John Bolla appointed as new President of UPS Healthcare

UPS announced the retirement of Wes Wheeler who served as president of UPS Healthcare division over the last three and a half years. He previously served as the CEO of Marken, before its acquisition by UPS in 2016 and then quickly pivoted to launch UPS’s healthcare vertical, building specialized capability and redoubling UPS’s commitment to the patient.

John Bolla joined UPS in April 2022, responsible for global healthcare logistics and distribution where he successfully led the business across UPS’s Americas, Europe and Asia Pacific Middle East and Africa (AMEA) operations.

“I am grateful for the opportunity to lead UPS Healthcare and more than 10,000 healthcare logistics experts and a global network spanning 220 countries and territories worldwide,“ said UPS Healthcare President John Bolla. “Together with this team of dedicated professionals, we will continue helping healthcare companies make their operations more precise, productive, scalable and smart.”

Prior to joining UPS, he served as chief operations officer at Adare Pharma Solutions where he was responsible for global sales, operations, contract development and manufacturing strategy across the U.S and Europe.

“John brings a wealth of healthcare and pharmaceutical experience after a long career in the pharmaceuticals and medical device industry,” said Executive Vice President and President of UPS International, Healthcare and Supply Chain Solutions Kate Gutmann. “I am confident that under his leadership, UPS Healthcare will continue on its path to accelerated growth.”

For 22 years, John worked at GlaxoSmithKline (GSK), one of the world’s largest pharmaceutical companies, providing leadership in areas such as manufacturing operations, supply chain, procurement and external supply/CDMO. During his time at GSK, John held several positions across various functions eventually rising to the role of vice president of North American supply chain, then senior vice president of third-party sales and contract manufacturing.

After leaving GSK, John joined Lantheus Holdings – a global specialty pharma and imaging company delivering novel diagnostic and therapeutic products in the oncology sector – as chief operations officer, where he led commercial and technical performance across the entire company.